High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial. | ClinicLens

Brain metastases in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) frequently contribute to treatment failure. This phase II study aims to evaluate furmonertinib (160 mg daily) in 40 untreated patients with EGFR-mutant NSCLC and central nervous

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.